Journal article
The effects of inhaled aztreonam on the cystic fibrosis lung microbiome
Abstract
BackgroundAztreonam lysine for inhalation (AZLI) is an inhaled antibiotic used to treat chronic Pseudomonas aeruginosa infection in CF. AZLI improves lung function and quality of life, and reduces exacerbations-improvements attributed to its antipseudomonal activity. Given the extremely high aztreonam concentrations achieved in the lower airways by nebulization, we speculate this may extend its spectrum of activity to other organisms. As such, …
Authors
Heirali AA; Workentine ML; Acosta N; Poonja A; Storey DG; Somayaji R; Rabin HR; Whelan FJ; Surette MG; Parkins MD
Journal
Microbiome, Vol. 5, No. 1,
Publisher
Springer Nature
Publication Date
December 2017
DOI
10.1186/s40168-017-0265-7
ISSN
2049-2618